Clinical Trial Update: A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 randomized trial comparing ixabepilone (Ixempra) with paclitaxel (Taxol) as adjuvant therapy for triple-negative breast cancer has completed with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Ixempra (ixabepilone)
• Taxol (paclitaxel)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2017-04-12